Aigan Co. Adjusts Valuation Metrics, Highlighting Financial Health and Growth Potential

Aigan Co., Ltd., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the company's valuation metrics, highlighting various financial indicators that are essential for understanding its market position. The company's P/E ratio stands at 20, while its Price to Book Value is noted at 0.46, suggesting a relatively low valuation compared to its book value. Additionally, Aigan Co. has reported an EV to EBIT of 9.43 and an EV to EBITDA of 4.27, which are indicative of its operational efficiency. The PEG ratio is recorded at 0.08, further emphasizing the company's growth potential relative to its earnings. Despite a modest annual growth rate in net sales of 2.22% and an operating profit growth of 17.99% over the past five years, Aigan Co. has shown a net profit of JPY 278.18 million for the half-year ending December 2025. The return on equity (ROE) is at 2.25%, while the return on capital employed (ROCE) has reached its highest at 1.88%. Overall, the recent evaluation adjustment reflects a nuanced view of Aigan Co.'s financial health and market dynamics. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.